微小染色体维持蛋白2在脑胶质瘤中的表达

The expression of MCM2 in human glioma.

目的探讨微小染色体维持蛋白2（MCM2）在脑胶质细胞瘤中表达的意义及与Ki67的关系。方法应用免疫组织化学SABC法检测35例胶质瘤组织和5例正常脑组织中MCM2和Ki67的表达情况。结果MCM2、和Ki67在正常脑组织中不表达，胶质瘤中MCM2和Ki67的表达随肿瘤病理级别的增加而增加，MCM2和Ki67的表达呈明显正相关（r=0．832，P〈0．001）。而MCM2要比Ki67高，尤其在Ⅰ-Ⅱ级之间（PMCM2=0．004，PKi67=0．502）和Ⅲ-Ⅳ级之间（PMCM2=0．002，PKi67=0．039）。MCM2和Ki67的标记指数在生存时间≥2年组和生存时间〈2年组差异均具有显著性（P=0．001；P=0．032），胶质瘤中MCM2和Ki67的表达在不同性别、年龄间的比较，差异均无显著性（P〉0．05）。结论MCM2比Ki67在脑胶质瘤中能更好地反映细胞的增殖情况，并对预后判断更有指导意义。

Objective To explore MCM2 expression in human glioma and the relationship between its expression and Ki67. Methods Expression of MCM2 and Ki67 were assessed by immunohistochemistry staining in 35 cases of gliomas and 5 normal brain tissues. Results No expressions of MCM2 and Ki67 were found in the normal brain tissues. Statistical significant differences of MCM2 and Ki67 LI were observed in different pathologic grades of brain glioma. There was a positive correlation between the expression of MCM2 and Ki67（ r =0.832 , P 〈0.001 ）. MCM2LI was higher than Ki67LI, especialy in grade Ⅰ - Ⅱ and grade Ⅲ -Ⅳ. The expressions of MCM2 and Ki67 were detected in a significantly lower labelling index in 1≥2 years of survival time of patients with gliomas than in 〈 2 years of survival time of patients （ P = 0. 001 ; P = 0.032 ） , but not related with sex and age. Conclusion MCM2 can well reflect cell proliferation in glioma than Ki67 and is more likely to be of prognostic value.